Author：Institute of Clinical Basic Medicine of Traditional Chinese Medicine, Chinese Academy of Sciences

Abstract：

Journal：National Medical Journal of China

Publishing Time：2020,100(00):E021-E021

DOI：10.3760/cma.j.issn.0376-2491.2020.0021

Author：

Abstract：

Journal：International journal of biological sciences

Publishing Time：

DOI：10.7150/ijbs.45538

Author：

Abstract：

Journal：Pharmacological research

Publishing Time：

DOI：10.1016/j.phrs.2020.104768

Author：

Abstract：

Journal：Pharmacological research

Publishing Time：

DOI：10.1016/j.phrs.2020.104743

Author：

Abstract：

Journal：Pharmaceuticals

Publishing Time：

DOI：10.3390/PH13030051

Author：

Abstract：

Journal：中国结合医学杂志(英文版)

Publishing Time：

DOI：10.1007/s11655-020-3192-6

Author：

Abstract：

Journal：柳叶刀·风湿病学

Publishing Time：

DOI：10.1016/S2665-9913(20)30089-8

Author：

Abstract：

Journal：The Journal of rheumatology

Publishing Time：

DOI：10.3899/jrheum.200334

Author：

Abstract：

Journal：Herald of Medicine

Publishing Time：

DOI：

Author：Xu Dongyu

Abstract： Objective：To study Qingfeipaidu decoction and its mechanism in the treatment of COVID-19 based on network pharmacology. Methods：TCMSP database was used to search and screen the active components of Qingfeipaidu decoction, and GeneGards database was used to predict and screen the disease target, the active component-target network diagram was established. STRING was used to construct protein-protein interaction (PPI) network. Gene Ontology (Go) and KEGG enrichment analysis were performed, the target signal pathway network map was drawn. Results：A total of 217 targets of traditional Chinese medicine and 200 targets of COVID-19 were screened, then 51 common drug-disease targets were obtained, mostly enriched in biological processes and 30 signaling pathways, such as TNF signaling pathway, IL-17 signaling pathway, NF-κB signaling pathway and Th17 cell differentiation. Conclusion：The five main active components of Qingfeipaidu decoction in the treatment of COVID-19 are quercetin, luteolin, kaempferol, naringin and isorhamnetine. They can inhibit inflammatory reaction, regulate immune function, reduce lung injury and protect nerve function by regulating targets to achieve the purpose of treating COVID-19, such as mapk1, mapk3, mapk8, Mapk14, IL6, RELA and STAT1 and so on.

Journal：Pharmacology and Clinics of Chinese Materia Medica

Publishing Time：

DOI：10.13412/j.cnki.zyyl.20200305.001

Author：

Abstract：

Journal：Journal of Traditional Chinese Medicine

Publishing Time：

DOI：

Author：QIN Zi-nan

Abstract： Qingfei Paidu Decoction is a traditional Chinese medicine compound recommended by National Health Commission of the People's Republic of China and National Administration of Traditional Chinese Medicine for clinical therapies of corona virus disease 2019 (COVID-19). Qingfei Paidu Decoction consists of 21 traditional Chinese medicines, such as Asari Radix et Rhizoma. However, the dosage of Asari Radix et Rhizoma has been questioned by some people, because of one ancient proverb. To explore the rationality of the dosage of Asari Radix et Rhizoma in Qingfei Paidu Decoction, this study systematically examined the ancient and modern physicians' understanding of the toxicity of Asari Radix et Rhizoma, and collated the application and dosage of Asari Radix et Rhizoma in ancient prescriptions and modern clinics based on literature analysis. As a result, we found that ancient and modern physicians have different understanding on the toxicity of Asari Radix et Rhizoma and that the theory about the dosage of Asari Radix et Rhizoma is flawed. We also found that the dose of Asari Radix et Rhizoma in ancient and modern clinical applications was not constrained by ancient experience. Physicians usually increase the dosage of Asari Radix et Rhizoma in clinical therapy according to the actual conditions, and there were no adverse reactions. Additionally, according to laws and regulations concerning medical affairs, physician could increase or decrease the dosage of the drug under special circumstances. Based on the analysis of safety and effectiveness of Asari Radix et Rhizoma in Qingfei Paidu Decoction, we conclude that the dose of Asari Radix et Rhizoma in Qingfei Paidu Decoction is safe, effective and reasonable.

Journal：China Journal of Chinese Materia Medica

Publishing Time：

DOI：10.19540/j.cnki.cjcmm.20200305.501

Author：YUAN Rong

Abstract： The global outbreak of novel coronavirus disease 2019 (COVID-19) has further spread, and there is an increasing number of confirmed cases in many countries. On February 28, 2020 of Geneva time, the World Health Organization has raised global risk level to the very high level in view of outbreak of COVID-19. Since some patients` condition appeared to deteriorate rapidly after infected with 2019 novel coronavirus (2019-nCoV), a variety of treatments should be considered. Holistic view and syndrome differentiation are the two characteristics of traditional Chinese medicine (TCM). Therefore, under the guidance of the holistic view, syndrome differentiation of TCM has achieved good effects in the treatment of COVID-19. This treatment mainly aimed at eliminating pathogens and strengthening healthy energy, regulating the balance of body and coordinating various of functions of Zangfu organs. In addition, modern medical proposes host-directed therapy (HDT), this strategy is to interfere with host cell mechanism, enhance immune responses, and reduce exacerbated inflammation. To some extent, the combined application of HDT and antiviral therapy is highly consistent with the therapeutic concept of the holistic view of TCM. Therefore, under the guidance of the holistic view, syndrome differentiation of TCM using clearing heat, detoxification, relieving asthma, clearing damp and phlegm etc treatments, and using Lianhua Qingwen Capsules, Maxing Shigan Decoction, Haoqin Qingdan Decoction etc under the guidance of these therapeutic methods. These therapeutic methods and prescriptions intervened both virus and host at the same time in the treatment of COVID-19, which has important implications for the effective clinical treatment of COVID-19.

Journal：China Journal of Chinese Materia Medica

Publishing Time：

DOI：10.19540/j.cnki.cjcmm.20200304.501